Patents by Inventor Jan Tavernier

Jan Tavernier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FIBROBLAST BINDING AGENTS AND USE THEREOF
    Publication number: 20240148824
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: January 2, 2024
    Publication date: May 9, 2024
    Inventors: Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS
  • Fibroblast binding agents and use thereof
    Patent number: 11896643
    Abstract: The present invention relates, in part, to agents that bind fibroblast activation protein (FAP) and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the FAP binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: February 13, 2024
    Assignee: Orionis Biosciences, Inc.
    Inventors: Nikolai Kley, Jan Tavernier, Anje Cauwels
  • THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
    Publication number: 20240025980
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 25, 2024
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE, Anje CAUWELS
  • TARGETED THERAPEUTIC AGENTS AND USES THEREOF
    Publication number: 20230399406
    Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
    Type: Application
    Filed: April 18, 2023
    Publication date: December 14, 2023
    Inventors: Jan TAVERNIER, Nikolai KLEY
  • PD-1 AND PD-L1 BINDING AGENTS
    Publication number: 20230295304
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: October 5, 2022
    Publication date: September 21, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • IMMUNOSTIMULATORY ADJUVANTS
    Publication number: 20230293652
    Abstract: The present invention relates, in part, to vaccine compositions, adjuvants, chimeric proteins, or chimeric protein complexes and their use as vaccines or therapeutic agents. The present invention further relates to methods of vaccination or treatment of various diseases.
    Type: Application
    Filed: July 7, 2021
    Publication date: September 21, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Frank PEELMAN, Sarah GERLO, Bram VAN DEN EECKHOUT
  • BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20230287131
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Application
    Filed: May 30, 2023
    Publication date: September 14, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Leander HUYGHE, Thomas WUEEST
  • Therapeutic targeting of non-cellular structures
    Patent number: 11753463
    Abstract: The present invention relates, in part, to chimeric proteins that bind a non-cellular structure and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: September 12, 2023
    Assignee: Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Leander Huyghe, Anje Cauwels
  • TARGETED MODIFIED IL-1 FAMILY MEMBERS
    Publication number: 20230235086
    Abstract: The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.
    Type: Application
    Filed: February 1, 2023
    Publication date: July 27, 2023
    Inventors: Jan TAVERNIER, Sarah GERLO, Frank PEELMAN, Gilles UZE
  • Bi-functional chimeric proteins and uses thereof
    Patent number: 11702477
    Abstract: The present invention relates, in part, to targeted chimeric proteins with beneficial therapeutic effects, including, for example, effects mediated by mutant forms of soluble agents that are part of the chimeric proteins. Pharmaceutical compositions comprising the chimeric proteins are also provided. The present invention finds use in the treatment of various disease and disorders.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: July 18, 2023
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Leander Huyghe, Thomas Wueest
  • Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
    Patent number: 11661455
    Abstract: The present invention relates, in part, to chimeric proteins that find use in various immunotherapies. Particularly, the present invention provides targeted therapeutic agents that modulate the immune system for the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: May 30, 2023
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Jan Tavernier, Nikolai Kley
  • CD8 BINDING AGENTS
    Publication number: 20230142099
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Application
    Filed: December 1, 2022
    Publication date: May 11, 2023
    Inventors: Nikolai KLEY, Jan TAVERNIER, Lennart ZABEAU, Erik DEPLA
  • THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
    Publication number: 20230103946
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Application
    Filed: July 21, 2022
    Publication date: April 6, 2023
    Inventors: Nikolai KLEY, Erik DEPLA, Lennart ZABEAU, Jan TAVERNIER
  • FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
    Publication number: 20230054612
    Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Inventors: Jan TAVERNIER, Jennyfer BULTINCK, Sarah GERLO, Gilles UZE, Franciane PAUL, Yann BORDAT
  • CD8 binding agents
    Patent number: 11566072
    Abstract: The present invention relates, in part, to agents that bind CD8 and their use as therapeutic and diagnostic agents. The present invention further relates to pharmaceutical compositions comprising the CD8 binding agents and their use in the treatment of various diseases, including, for example, cancers.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: January 31, 2023
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • PD-1 and PD-L1 binding agents
    Patent number: 11498966
    Abstract: The present invention relates, in part, to agents that bind PD-1 or PD-L1 and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the PD-1 or PD-L1 binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: November 15, 2022
    Assignees: Orionis Biosciences Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • CLEC9A BINDING AGENTS
    Publication number: 20220356253
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Application
    Filed: April 5, 2021
    Publication date: November 10, 2022
    Inventors: Jan TAVERNIER, Nikolai KLEY, Anje CAUWELS, Sarah GERLO
  • TARGETED MODIFIED TNF FAMILY MEMBERS
    Publication number: 20220324929
    Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 13, 2022
    Inventors: Jan TAVERNIER, Jennyfer BULTINCK, Frank PEELMAN, Gilles UZE
  • Therapeutic interferon alpha 1 proteins
    Patent number: 11440943
    Abstract: The present invention relates, in part, to chimeric proteins or chimeric protein complexes, such as Fc-based chimeric protein complexes, comprising interferon alpha 1, or a variant thereof, and their use as therapeutic agents.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: September 13, 2022
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Erik Depla, Lennart Zabeau, Jan Tavernier
  • TARGETED CHIMERIC PROTEINS AND USES THEREOF
    Publication number: 20220281992
    Abstract: The present invention relates, in part, to chimeric proteins comprising at least one targeting moiety that recognizes and binds SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.
    Type: Application
    Filed: May 16, 2022
    Publication date: September 8, 2022
    Inventors: Nikolai KLEY, Jan TAVERNIER